Form 4 for PLX Protalix BioTherapeutics, Inc.
Accepted 2025-12-23 00:00:00 ET · period of report 2025-12-19 · accession 0001781450-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-23 | 2025-12-19 | PLX | Bashan Dror | Pres AND CEO, Dir | P - Purchase | $1.81 | +56.0K | 188.5K | +42% | +$101.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-19 | P | A | 56,000 | $1.81 | 188,516 | D | — | — |